219 related articles for article (PubMed ID: 8024362)
1. Anti-endotoxin therapy in primate bacteremia with HA-1A and BPI.
Rogy MA; Moldawer LL; Oldenburg HS; Thompson WA; Montegut WJ; Stackpole SA; Kumar A; Palladino MA; Marra MN; Lowry SF
Ann Surg; 1994 Jul; 220(1):77-85. PubMed ID: 8024362
[TBL] [Abstract][Full Text] [Related]
2. The role of bactericidal/permeability-increasing protein in the treatment of primate bacteremia and septic shock.
Rogy MA; Oldenburg HS; Calvano SE; Montegut WJ; Stackpole SA; Van Zee KJ; Marra MN; Scott RW; Seilhammer JJ; Moldawer LL
J Clin Immunol; 1994 Mar; 14(2):120-33. PubMed ID: 8195314
[TBL] [Abstract][Full Text] [Related]
3. Endotoxin-binding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5.
Marra MN; Thornton MB; Snable JL; Wilde CG; Scott RW
Crit Care Med; 1994 Apr; 22(4):559-65. PubMed ID: 8143464
[TBL] [Abstract][Full Text] [Related]
4. Comparison of a recombinant endotoxin-neutralizing protein with a human monoclonal antibody to endotoxin for the treatment of Escherichia coli sepsis in rats.
Kuppermann N; Nelson DS; Saladino RA; Thompson CM; Sattler F; Novitsky TJ; Fleisher GR; Siber GR
J Infect Dis; 1994 Sep; 170(3):630-5. PubMed ID: 8077721
[TBL] [Abstract][Full Text] [Related]
5. Comparison of peripheral blood leukocyte kinetics after live Escherichia coli, endotoxin, or interleukin-1 alpha administration. Studies using a novel interleukin-1 receptor antagonist.
Hawes AS; Fischer E; Marano MA; Van Zee KJ; Rock CS; Lowry SF; Calvano SE; Moldawer LL
Ann Surg; 1993 Jul; 218(1):79-90. PubMed ID: 8328833
[TBL] [Abstract][Full Text] [Related]
6. Bactericidal/permeability-increasing protein protects vascular endothelial cells from lipopolysaccharide-induced activation and injury.
Arditi M; Zhou J; Huang SH; Luckett PM; Marra MN; Kim KS
Infect Immun; 1994 Sep; 62(9):3930-6. PubMed ID: 8063410
[TBL] [Abstract][Full Text] [Related]
7. Protection against endotoxic shock by bactericidal/permeability-increasing protein in rats.
Jin H; Yang R; Marsters S; Ashkenazi A; Bunting S; Marra MN; Scott RW; Baker JB
J Clin Invest; 1995 Apr; 95(4):1947-52. PubMed ID: 7706502
[TBL] [Abstract][Full Text] [Related]
8. Endotoxin-neutralizing properties of the 25 kD N-terminal fragment and a newly isolated 30 kD C-terminal fragment of the 55-60 kD bactericidal/permeability-increasing protein of human neutrophils.
Ooi CE; Weiss J; Doerfler ME; Elsbach P
J Exp Med; 1991 Sep; 174(3):649-55. PubMed ID: 1875165
[TBL] [Abstract][Full Text] [Related]
9. Peptide derivatives of three distinct lipopolysaccharide binding proteins inhibit lipopolysaccharide-induced tumor necrosis factor-alpha secretion in vitro.
Battafaraono RJ; Dahlberg PS; Ratz CA; Johnston JW; Gray BH; Haseman JR; Mayo KH; Dunn DL
Surgery; 1995 Aug; 118(2):318-24. PubMed ID: 7638748
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of the hemodynamic effects of HA-1A human monoclonal antibody.
Kett DH; Quartin AA; Sprung CL; Fisher CJ; Peña MA; Heard SO; Zimmerman JL; Albertson TE; Panacek EA; Eidelman LA
Crit Care Med; 1994 Aug; 22(8):1227-34. PubMed ID: 8045141
[TBL] [Abstract][Full Text] [Related]
11. Protective effects of a recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in an animal model of gram-negative sepsis.
Evans TJ; Carpenter A; Moyes D; Martin R; Cohen J
J Infect Dis; 1995 Jan; 171(1):153-60. PubMed ID: 7798655
[TBL] [Abstract][Full Text] [Related]
12. A recombinant tumor necrosis factor-alpha p80 receptor:Fc fusion protein decreases circulating bioactive tumor necrosis factor-alpha but not lung injury or mortality during immunosuppression-related gram-negative bacteremia.
Lechner AJ; Johanns CA; Matuschak GM
J Crit Care; 1997 Mar; 12(1):28-38. PubMed ID: 9075062
[TBL] [Abstract][Full Text] [Related]
13. A controlled trial of HA-1A in a canine model of gram-negative septic shock.
Quezado ZM; Natanson C; Alling DW; Banks SM; Koev CA; Elin RJ; Hosseini JM; Bacher JD; Danner RL; Hoffman WD
JAMA; 1993 May; 269(17):2221-7. PubMed ID: 8474201
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels.
Wortel CH; von der Möhlen MA; van Deventer SJ; Sprung CL; Jastremski M; Lubbers MJ; Smith CR; Allen IE; ten Cate JW
J Infect Dis; 1992 Dec; 166(6):1367-74. PubMed ID: 1431255
[TBL] [Abstract][Full Text] [Related]
15. Comparison of HA-1A and E5 monoclonal antibodies to endotoxin in rats with endotoxaemia.
Boom SJ; Davidson JA; Zhang P; Reidy J; Ramsay G
Eur J Surg; 1993 Oct; 159(10):559-61. PubMed ID: 8286515
[TBL] [Abstract][Full Text] [Related]
16. Implications of endotoxin contamination in the evaluation of antibodies to lipopolysaccharides in a murine model of gram-negative sepsis.
Chong KT; Huston M
J Infect Dis; 1987 Nov; 156(5):713-9. PubMed ID: 3309071
[TBL] [Abstract][Full Text] [Related]
17. Antibacterial proteins of granulocytes differ in interaction with endotoxin. Comparison of bactericidal/permeability-increasing protein, p15s, and defensins.
Levy O; Ooi CE; Elsbach P; Doerfler ME; Lehrer RI; Weiss J
J Immunol; 1995 May; 154(10):5403-10. PubMed ID: 7730641
[TBL] [Abstract][Full Text] [Related]
18. A synthetic peptide derived from bactericidal/permeability-increasing protein neutralizes endotoxin in vitro and in vivo.
Jiang Z; Hong Z; Guo W; Xiaoyun G; Gengfa L; Yongning L; Guangxia X
Int Immunopharmacol; 2004 Apr; 4(4):527-37. PubMed ID: 15099530
[TBL] [Abstract][Full Text] [Related]
19. Effect of lipopolysaccharide (LPS) chain length on interactions of bactericidal/permeability-increasing protein and its bioactive 23-kilodalton NH2-terminal fragment with isolated LPS and intact Proteus mirabilis and Escherichia coli.
Capodici C; Chen S; Sidorczyk Z; Elsbach P; Weiss J
Infect Immun; 1994 Jan; 62(1):259-65. PubMed ID: 8262637
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia.
Fischer E; Marano MA; Van Zee KJ; Rock CS; Hawes AS; Thompson WA; DeForge L; Kenney JS; Remick DG; Bloedow DC
J Clin Invest; 1992 May; 89(5):1551-7. PubMed ID: 1533231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
